AI Eye Scans Spot Diabetic Disease in Aussie Trial

Centre for Eye Research Australia

A new Australian study has found that an automated AI camera can accurately detect diabetic eye disease with more than 93% accuracy in non-eye care settings.

The study's authors – Associate Professor Lisa Zhuoting Zhu and Sanil Joseph from the Centre for Eye Research Australia and University of Melbourne, and Professor Mingguang He, of the Hong Kong Polytechnic University – say their findings demonstrate the potential AI eye screening to become part of routine clinical care for people with diabetes.

Globally, more than 529 million people are living with diabetes and at risk of vision loss and blindness from diabetic eye disease.

Early treatment can prevent blindness in 90 per cent of cases but ensuring that everyone with diabetes has access to the eye scans needed to detect the disease is a huge challenge for health systems worldwide.

Now the findings of a two-year Australian trial, published in the British Journal of Ophthalmology, show the potential of AI to increase access to sight saving eye screenings.

More than 860 people with diabetes took part in the trial in the waiting rooms of GP and endocrinology clinics in Melbourne and an Aboriginal Health Service in Western Australia between August 2021 and June 2023.

The trial used an automated portable retinal camera – powered by an AI algorithm trained on more than 200,000 retinal images graded by 21 ophthalmologists - to guide participants to take photos of their own eyes while they waited for their medical appointment.

Trial participants received a print-out with a QR code with results of their scan to take into their appointment, and those found to have signs of the disease referred for follow up with an eye care specialist.

To determine accuracy, all results were compared to the gold standard assessments of human grading. Participants and health professionals also took part in a satisfaction survey.

Although many studies have compared AI to human grading for diabetic eye disease, the Melbourne study is one of the first to occur in real world clinical settings.

The study found:

  • A high accuracy rate of 93.3% compared to human grading
  • 86% of participants were satisfied with the technology
  • 85% of clinicians rated the technology highly.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).